Antiretroviral Agents: Nucleoside Reverse Transcriptase Inhibitors

Quick Menu / Table of Contents
Introduction	Principles	Management	NRTI Key	NRTI Info
NNRTI Key	NNRTI Info	PI Key	PI Info	Fusion Inhibitors
Drug Summary	Investigational	Adherence	Lab Evaluation	Resistance Tests
PEP	Antiretroviral Tables	OI Prevention	Vaccinations	TB Therapy
Hepatitis Therapy	OI Diagnosis	OI Therapy	Bibliography	Links

emtricitabine

Detailed Prescribing Information

July 2006

Emtriva = emtricitabine = FTC Also a component of Truvada and Atripla
Forms Available	200 mg caps 200 mg emtricitabine with 300 mg tenofovir as Truvada 200 mg entricitabine with 600 mg efavirenz and 300 mg tenofovir as Atripla
Dosing	200 mg daily
	Renal dosing¹	Ccr (cc/min)	Dose (mg)
		> 50	200 daily
		30-49	200 q48h
		15-29	200 q72h
		<15	200 q96h
		hemodialysis	200 q96h give dose after dialysis
	Hepatic dosing: insufficient data, but there appears to be no hepatic metabolism
Food dependence	This medication may be taken with or without food.
Adverse Effects	Very well tolerated Diarrhea, nausea, rash at incidence similar to other agents Skin discoloration, usually mild and asymptomatic: palms and/or soles 3% Flare of hepatitis B if stopped suddenly.
Interactions	None significant
Suggested lab follow-up	None
Warning	Rare lactic acidosis Low barrier to one-step mutational resistance Possible flare of hepatitis B if emtricitabine is discontinued suddenly.
Suggested Usage	Do not use in combination with lamivudine, Truvada, Epzicom, Combivir, Atripla or Trizivir due to identical mechanism of action (with lamivudine) or duplication of emtricitabine dosing. Emtricitabine has a very low (one-step) barrier to resistance. Always ensure that emtricitabine is used with several potent and active antiretroviral agents. Do not discontinue abruptly in patients with chronic hepatitis B without consideration of continuation of lamivudine or some other agent active against hepatitis B.
Complete prescribing information	http://www.emtriva.com/fpi.pdf

Links to Antiretroviral Sections (click on anything)

Nucleoside & Nucleotide Reverse Transcriptase Inhibitors (NRTI)

AZT | ddC | ddI | d4T | 3TC | ABC | FTC | TDF | Combivir | Trizivir | Epzicom | Truvada | Atripla

Nonnucleoside Reverse Transcriptase Inhibitors (NNRTI)

efavirenz | nevirapine | delavirdine

Protease Inhibitors (PI) | Boosted Protease Inhibitors

Fusion Inhibitors

enfuvirtide

Quick Menu / Table of Contents
Introduction	Principles	Management	NRTI Key	NRTI Info
NNRTI Key	NNRTI Info	PI Key	PI Info	Fusion Inhibitors
Drug Summary	Investigational	Adherence	Lab Evaluation	Resistance Tests
PEP	Antiretroviral Tables	OI Prevention	Vaccinations	TB Therapy
Hepatitis Therapy	OI Diagnosis	OI Therapy	Bibliography	Links

7.14.2006

1. Renal dosing information from: Ian R. McNicholl & Rudolph A. Rodriguez, MD, Dosing of Antiretroviral Drugs in Renal Insufficiency and Hemodialysis, May 2004
http://hivinsite.ucsf.edu/InSite?page=md-rr-18